Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Edwin Elmhirst

Data Journalist

Edwin is a healthcare journalist with a passion for data and analysis. He graduated with a master's degree in biomedical sciences and spent some time in postgraduate research before moving into journalism. Edwin's skills in data science and scientific analysis allow him to identify trends, develop insights, and tell compelling stories using data.

Latest From Edwin Elmhirst

Analysis: Novo And Lilly Make Their Money Work

Pharma groups must decide how best to invest their cash to generate the biggest returns, and while huge sums can be made with luck and good judgement, strategic missteps can have far-reaching consequences.

Companies Strategy

Scrip M&A Podcast: Which Companies Could Be Acquired Next?

The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.

M & A Business Strategies

AbbVie Needs To Freshen Up

With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.

Commercial Companies

Private Equity And VC Fund Data: What Do The Numbers Show?

In Vivo examines trends in the venture capital and private equity funding landscapes for biotech and pharma – looking at both expenditure and gathering of capital resources.

Companies Deals

Unpartnered Assets To Watch In 2024

Licensing serves as a strategic R&D avenue for major developers amid a shrinking M&A market. In Vivo has detected five high-value unpartnered assets that might be the focus of dealmaking activity in the coming months. 

Growth Commercial

The Biggest Drug Launches Expected In 2024

A rundown of the ten most valuable drug launches expected in 2024 from both big pharma and some first-to-market companies. 

Launches Companies
See All